COMMUNIQUÉS West-GlobeNewswire

-
Specialty Renal Products Announces $3 Million Series A Financing
06/09/2018 -
Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors
06/09/2018 -
Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
06/09/2018 -
Innovate Biopharmaceuticals to Host Clinical and Scientific Update Event on Thursday, September 6, 2018, in New York City.
06/09/2018 -
Orphazyme to Present at BioCentury 25th Annual NewsMakers in the Biotech Industry
06/09/2018 -
UPDATE: Emblem signs five-year supply agreement with Compass Cannabis Clinic for Starbuds Canada
06/09/2018 -
Intrommune Therapeutics Completes Pre-IND Meeting With FDA on INT301 for Peanut Allergy
06/09/2018 -
CMS Rating for Amedisys Home Health Improves for 11th Consecutive Quarter
06/09/2018 -
Cutera Announces Regulatory Clearance of truSculpt® iD in Canada
06/09/2018 -
Medibio Clinical Study Shows Over 20% Improvement to Current Diagnostic Standard
06/09/2018 -
Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets
06/09/2018 -
BeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 Trial
06/09/2018 -
Auxly and Delta 9 Announce Strategic Investment and Supply Agreement
06/09/2018 -
CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile
06/09/2018 -
Emerald Health Therapeutics Announces Amendment from Health Canada for Pure Sunfarms’ Cultivation License, Expanding Cannabis Production Area to Approximately 550,000 Square Feet in One of the Single Largest Cannabis Growing Facilities in the World
06/09/2018 -
Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program
06/09/2018 -
TRU NIAGEN® to be Highlighted at Vitafoods Asia 2018 in Singapore
06/09/2018 -
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy
06/09/2018 -
Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise
06/09/2018
Pages